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ABSTRACT 
Solid organ transplant (SOT) recipients are exposed to respiratory viral infection (RVI) during 
seasonal epidemics; however, the associated burden of disease has not been fully characterized. 
We describe the epidemiology and outcomes of RVI in a cohort enrolling 3294 consecutive 
patients undergoing SOT from May 2008 to December 2015 in Switzerland. Patient and allograft 
outcomes, and RVI diagnosed during routine clinical practice were prospectively collected. 
Median follow-up was 3.4 years (interquartile range 1.61-5.56). Six-hundred-ninety-six RVI were 
diagnosed in 151/334 (45%) lung and 265/2960 (5%) non-lung transplant recipients. Cumulative 
incidence was 60% (95% confidence interval [CI] 53%-69%) in lung and 12% (95% CI 11%-
14%) in non-lung transplant recipients. RVI led to 17.9 (95% CI 15.7-20.5) hospital admissions 
per 1000 patient-years. Intensive care unit admission was required in 4% (27/691) of cases. Thirty-
day all-cause case fatality rate was 0.9% (6/696). Using proportional hazard models we found that 
RVI (adjusted-hazard ratio [aHR] 2.45; 95% CI 1.62-3.73), lower respiratory tract RVI (aHR 3.45; 
95% CI 2.15-5.52), and influenza (aHR 3.57; 95% CI 1.75-7.26) were associated with graft failure 
or death. In this cohort of SOT recipients, RVI caused important morbidity and may affect long-
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1. INTRODUCTION 
Respiratory viral infections (RVI) are caused by influenza, respiratory syncytial virus (RSV), 
human parainfluenza virus (HPIV), human metapneumovirus (HMPV), picornaviruses (including 
rhinovirus and enterovirus), human coronavirus (HCoV), human adenovirus (HAdV), and human 
bocavirus (HBoV). Influenza, RSV, HPIV, HMPV, and HCoV follow seasonal patterns, typically 
occurring in winter in temperate climates, while picornavirus is encountered throughout the year.1-
3 RVI mainly cause self-limited upper respiratory tract disease in the general population, although 
more severe infections, particularly with influenza and RSV, can occur in individuals with 
predisposing conditions, such as extreme age and coexisting medical conditions.4,5 
Solid organ transplant (SOT) recipients are generally at increased risk for a higher incidence and 
complications rate of viral diseases due to lifelong immunosuppression.6 In addition, viral 
infections may trigger immune and non-immune mechanisms potentially leading to acute 
rejection, inflammatory and fibrotic changes, and ultimately graft dysfunction and loss.7 Given 
their widespread exposure during seasonal epidemics, RVI can be potentially associated with 
significant burden of disease in SOT recipients.8 
To date, most studies in SOT recipients have focused on lung transplant recipients and the 
association of RVI with chronic lung allograft dysfunction (CLAD), the principal cause of 
mortality in this population.9-12 For non-lung transplant recipients, studies are mainly limited to the 
description of clinical manifestations and outcomes of influenza.13 
In this study we aimed to assess the epidemiology, outcomes, and impact on graft and patient 
survival of RVI in a large prospective cohort of SOT recipients involving both lung and non-lung 
transplant recipients.
2. METHODS
2.1. Study design and participants
The Swiss Transplant Cohort Study (STCS) is a prospective, observational cohort enrolling 
consecutive patients undergoing organ transplantation in Switzerland since May 2008.14 For this 
study, we included all patients enrolled from May 2008 until December 2015, and we considered a 
follow-up until June 30th 2016 (censoring), or end of follow-up due to dropout, first graft-loss or 
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All patients provided written informed consent. The local ethics committees at each center 
approved the STCS. The local Ethics Committee at the Lausanne University Hospital approved the 
protocol of the present study (Protocol number 2017-01146). 
2.2. Data collection
In the STCS, clinical and laboratory data (including comorbidities, graft related outcomes, 
immunosuppression drugs, surgical and medical complications, and infectious diseases events) are 
prospectively collected from hospital electronic databases and referral documentations in a 
standardized electronic case report form for all participants at transplantation, 6 and 12 months 
after transplantation, and yearly thereafter, as previously described.14 In particular, infectious 
diseases events are collected by transplant infectious diseases specialists according to the 
definitions developed by the STCS Infectious Diseases Working Group based on the 
recommendation of the American Society of Transplantation Infectious Disease Community of 
Practice (AST-IDCOP) and the European Conference on Infections in Leukemia (ECIL).6,15,16 
Microbiological tests for the diagnosis of infectious diseases are chosen and performed at each 
center when deemed indicated as a part of routine practice. We identified the episodes of RVI 
through search for microbiologically confirmed influenza A and B, RSV A and B, HPIV 1 to 4, 
HMPV, picornaviruses (including rhinovirus and enterovirus), seasonal HCoV HKU1, 229E, 
OC43, and NL63, HAdV, and HBoV infections in the STCS database during the study period. We 
verified each episode of RVI by chart review at each of the participating transplant centers, and for 
each episode of infection we retrospectively collected additional variables not included in the 
STCS database. Prospectively and retrospectively collected variables used in this study are 
described in the Supplementary Table S1. 
2.3. Definition and outcomes
RVI was defined as the detection of influenza (A and B), RSV (A and B), HPIV (1-4), HMPV, 
picornaviruses (including rhinovirus and enterovirus), HCoV (HKU1, 229E, OC43, and NL63), 
HAdV, or HBoV in a respiratory sample (nasal, pharyngeal or nasopharyngeal swabs, sputum, 
bronchoalveolar lavage, and bronchial or tracheal aspirate), by nucleic acid amplification test or 
antigen detection. In case of simultaneous isolation of more than one virus, the episode of RVI 
was considered influenza when influenza was present, RSV when RSV was present and no 
influenza was detected, and mixed infection otherwise. When the same virus was isolated 
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documented in between, or when the 2 samples occurred more than 90 days apart. We further 
classified RVI in asymptomatic RVI, upper respiratory tract infection (URTI), and lower 
respiratory tract infection (LRTI) according to the ECIL-4 guidelines with slight modifications 
(Supplementary Table S2).15 Radiologic infiltrate was considered present when described by the 
radiologist in clinical charts. Bacterial or fungal co-infection were defined as the isolation of 
bacteria or fungi by culture in a respiratory sample or in blood, or in presence of indirect evidence 
of infection (i.e. positive urinary antigen for Streptococcus pneumoniae or positive galactomannan 
in bronchoalveolar lavage or serum for Aspergillus spp.) following or concomitant to RVI. RVI 
was defined nosocomial and intensive care unit (ICU) acquired when occurring at least 3 days 
after hospital or ICU admission, respectively. Graft failure was defined as re-transplantation, death 
due to cardiac, respiratory, hepatic or renal failure according to the type of transplant, return to 
dialysis for kidney transplant recipients, or recurrence of insulin-dependent diabetes for pancreas 
and islets transplant recipients. 
The descriptive primary outcomes of the study were the incidence of microbiologically confirmed 
RVI in lung and non-lung transplant recipients, the need of hospital admission for RVI, and all-
cause mortality 30 days after RVI. The secondary outcomes were a composite endpoint of graft 
failure or death, and the occurrence of severe RVI (defined as need for ICU admission). RVI, 
LRTI, and influenza were the exposures for the composite secondary outcome of death and graft 
failure. 
2.4. Statistical analysis
We used descriptive statistics to illustrate baseline characteristics of study participants with and 
without RVI, and characteristics of RVI episodes. Categorical variables were represented as 
numbers and percentages, and continuous variables as medians and interquartile ranges (IQR) and 
compared using respectively two-sided Fischer’s exact test or Chi2 test, and t test or Mann-
Whitney U test, as appropriate. Cumulative incidence of first RVI and of each specific RVI were 
calculated treating death and graft failure before infection as competing risks. We used 
multivariable logistic regression to identify risk factors for severe RVI. Co-variates with 
significant association in univariate analysis were included in the multivariable model, forcing sex 
and lung transplantation into the model.  We used Cox proportional-hazards models to assess the 
association between RVI (and LRTI, and influenza) and graft failure or death with non-
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an event lasting for 180 days after the event was recorded. RVI was coded as a multi-level factor, 
which had the levels “LRTI”, “Influenza”, “Influenza with LRTI”, “other RVI” and “no RVI”. 
Other baseline and time-varying risk factors for graft failure or death were selected as previously 
described with slight modifications and are illustrated in Supplementary Table S3.17 To determine 
the hazard ratios (HR) comparing RVI vs. no RVI, LRTI vs. no LRTI, and influenza vs. no 
influenza, we calculated contrasts for the weighted average log-transformed HR for the 
appropriate levels of the RVI factor. P-values and confidence intervals for these model contrasts 
were corrected for multiple testing based on the joint t distribution of the linear contrast function.18 
Because of the expected higher incidence of RVI and reduced graft failure-free survival in lung 
transplant recipients, all models were fit in the whole cohort and separately in lung and non-lung 
transplant recipients. P-value <0.05 was considered significant. The statistical software R version 




Between May 2008 and December 2015, 3294 (93%) of 3548 patients undergoing organ 
transplantation were enrolled in the STCS. We included in this study 1826 kidney, 685 liver, 249 
heart, 334 lung, 161 combined transplant recipients, and 39 recipients of other allografts (28 islets, 
10 pancreas, and 1 small bowel). Median age at enrollment was 54.0 years (interquartile range 
[IQR] 41.0-62.0), and 2107 (64.0%) of the participants were male. Most of the patients received 
induction immunosuppression with basiliximab (69.5% [2288/3294]) and were kept on a 
maintenance immunosuppression with tacrolimus (71.7% [2360/3294), mycophenolate (89.9% 
[2961/3294]) and prednisone (91.3% [3006/3294]) at hospital discharge after transplantation. 
Median follow-up was 3.40 years (IQR 1.61-5.56), corresponding to a total of 12316 person-years 
of follow-up (Table 1). 
3.2. Epidemiology of respiratory viral infections
Overall, 696 episodes of RVI (236 picornavirus [33.9%], 186 influenza [26.7%], 77 RSV [11.1%], 
66 HCoV [9.5%], 49 HPIV [7.0%], 31 HMPV [4.5%], 10 HAdV [1.4%], 5 HBoV [0.7%], and 36 
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(Table 2). Cumulative incidence was 60% (95% confidence interval [CI] 53%-69%) in lung and 
12% (95% CI 11%-14%) in non-lung transplant recipients (Figure 1, panel A). Incidence rate of 
RVI was 320.0 (95% CI 287.5-355.2) and 30.6 (95% CI 27.4-34.0) RVI per 1000 person-years in 
lung and non-lung transplant recipients, respectively. The most common RVI in lung transplant 
recipients was picornavirus (cumulative incidence 40%, 95% CI 34%-48%) (Figure 1, panel B). In 
contrast, in non-lung transplant recipients the most common virus was influenza with a cumulative 
incidence of 7.5% (95% CI 6.1%-9.1%) (Figure 1, panel C). Incidence rate per 1000 patient-years 
was 149.6 (95% CI 127.6-174.2) for picornavirus in lung, and 13.1 (95% CI 11.1-15.4) for 
influenza in non-lung transplant recipients (incidence rates for each RVI are detailed in the 
Supplementary Table S4). While picornavirus was present all year-round, influenza, RSV, HCoV 
and HMPV occurred principally in winter and HPIV in spring and fall, during seasonal epidemics 
(Figure 2). 
3.3. Characteristics and management of respiratory viral infections
Respiratory virus were detected by nucleic acid amplification test in 675 (97%) of 696 episodes of 
infection, by antigenic detection in 10 episodes, and the method of detection was unknown in 11 
episodes. Clinical characteristics of each respiratory virus are illustrated in Table 2; see 
Supplementary Table S4 for a detailed description of RVI according to type of transplantation. 
RVI were asymptomatic in 13.3% (47/353) of the episodes in lung transplant recipients, 70.2% 
(33/47) of those asymptomatic RVI were due to picornavirus or HCoV. Only nine (2.6%) of 343 
RVI in non-lung transplant recipients were asymptomatic, eight of them due to picornavirus. 
Progression to LRTI was common (242 [34.8%] of 696 RVI), in particular with HMPV (20 
[64.5%] of 31), HPIV (24 [49.0%] of 49), RSV (32 [41.6%] of 77), and influenza (68 [36.6%] of 
186). Chest imaging was performed in 313 (45.0%) and radiologic infiltrates were present in 132 
(19.0%) of 696 RVI episodes. Bacterial co-infections were documented in 7.6% (53; 15 
Pseudomonas aeruginosa, 11 Streptococcus pneumoniae, 11 Haemophilus influenzae, 2 
Staphylococcus aureus, and 14 other bacteria) and fungal co-infection in 3.4% (24; 18 Aspergillus 
spp, 5 Pneumocystis, and 1 Fusarium spp) of 696 RVI. Antibiotics or antifungals were 
administered in all cases of bacterial or fungal coinfections. 
Antivirals (oral oseltamivir in 145 and inhaled zanamivir in one episode) were used for treatment 
in 146 (78.5%) of 186 influenza episodes. In lung transplant recipients, oral ribavirin was used in 
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infections. Only two RSV episodes were treated with oral ribavirin in non-lung transplant 
recipients. 
3.4. Outcomes of respiratory viral infections
Hospital and ICU admission were required in 221 (34.2%) of 646 community acquired RVI (50 
additional RVI were nosocomial-acquired) and 27 (3.9%) of 691 RVI (five infections were 
acquired during ICU stay), respectively (Table 2). Calculated hospital admission incidence was 
17.9 (95% CI 15.7-20.5) per 1000 person-years overall, 71.6 (95% CI 56.7-89.3) per 1000 person-
years in lung, and 12.7 (95% CI 10.7-14.9) per 1000 person-years in non-lung transplant 
recipients. Overall, all-cause 30-day mortality and case fatality rate of RVI were 0.18% (six of 
3294 SOT recipients) and 0.9% (six of 696 RVI), respectively (Table 2). Calculated RVI 30-day 
all-cause mortality rate was 0.49 (95% CI 0.18-1.06) per 1000 patient-years. Specifically for 
influenza, calculated hospital admission incidence and all-cause 30-day mortality rate were 5.93 
(95% CI 4.65-7.45) and 0.16 (95% CI 0.02-0.59) per 1000 person-years. 
In multivariable logistic regression analysis, RVI acquisition by nosocomial infection (adjusted 
odds ratio [aOR] 4.8; 95% CI 1.7-13.0; p=0.0028), microbiologically confirmed bacterial co-
infection (aOR 5.1; 95% CI 1.8-14.0; p=0.0016), and presence of radiologic infiltrates (aOR 5.4; 
95% CI 2.1-15.0; p=0.0007) were significantly associated with severe RVI requiring ICU 
admission (Table 3). 
3.5. Association of respiratory viral infection with patient and allograft survival
In a Cox proportional hazard model, RVI was associated with an increased hazard of death or graft 
failure compared to no-RVI across all types of organ transplantation in our cohort (adjusted hazard 
ratio [aHR] 2.45 [95% CI 1.62-3.73]; p<0.0001) (Figure 3, panel A). In addition to RVI, age, male 
sex, pediatric transplantation, lung transplantation, surgical complications, renal failure, bacterial 
and fungal infection, and allograft-specific viral infections and CMV, were all associated with 
increased risk of graft failure or death. Of importance, acute rejection was associated with graft 
failure or death (aHR 3.3; 95% CI 2.2-4.16; p<0.0001). While RVI were associated with graft loss 
or death specifically in non-lung transplant recipients (aHR 3.54, [95% CI 2.07-6.05]; p<0.0001) 
(Figure 3, panel C), the association was not present in lung transplant recipients (aHR 1.64, [95% 
CI 0.82-3.27]; p=0.21) (Figure 3, panel B). In contrast, LRTI was significantly associated with 
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lung (aHR 2.75, [95% 1.25-6.05]; p=0.0081) and in non-lung transplant recipients (aHR 4.59, 
[95% CI 2.49-8.44]; p<0.0001). Influenza was also associated with graft failure or death in the 
whole cohort (aHR 3.57 [95% CI 1.75-7.26]; p=0.00016), as well as in lung (aHR 5.41 [95% CI 
1.48-19.7]; p=0.0072) and in non-lung transplant recipients (aHR 3.0 [95% CI 1.24-7.25]; 
p=0.01). 
4. DISCUSSION
In this large nationwide cohort of SOT recipients prospectively followed after transplantation, 696 
microbiologically confirmed RVI occurred from May 2008 until June 2016, corresponding to an 
incidence rate of 320 and 30.6 per 1000 person-years in lung and non-lung transplant recipients, 
respectively. 
Limited prospective data exist on the epidemiology of RVI in SOT recipients other than lung, 
particularly in adults. Two studies including 55 to 98 non-lung transplant recipients reported crude 
incidences of microbiologically confirmed RVI ranging from 4% to 36% early after 
transplantation.19,20 In a study involving 152 SOT recipients followed during one winter season, an 
incidence of 0.9 respiratory illness per patient-year (80% without microbiological confirmation) 
was observed.21 Given low numbers, short follow-up, and inclusion of episodes without 
microbiological confirmation, little comparison can be made with our present results. In lung 
transplant recipients, reported epidemiology of RVI varies, depending on the screening protocols 
and microbiological tests used.10,12,22 In two recent prospective and multi-season studies, 0.7 to 0.8 
RVI per patient-year, mostly human rhinovirus, were reported when testing was performed within 
a systematic screening protocol.10,12 In comparison, the incidence was 0.4 per patient-year when 
testing was performed only in symptomatic patients.23 In pediatric SOT recipients, the incidence 
of RVI associated with hospital admission was 14.5% in a multicenter retrospective study 
including more than 1096 children.24 In our study, pediatric transplant recipients were rare (5%). 
Since in our cohort testing for RVI was performed as part of routine clinical practice and only 
microbiologically confirmed infections were included, incidence was lower than previously 
reported in SOT recipients and expected in the general population.10,12,21,25 Lower threshold for 
testing, and different patient’s behavior, may explain in part the higher incidence rates and 
proportion of less severe RVI in lung transplant recipients, as well as the different distribution of 
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bronchoscopies or by nasopharyngeal swab in case of worsening respiratory function, as an 
example, led to an increased detection of asymptomatic RVI in lung transplant recipients. Whether 
viral interaction dynamics and changes in social behavior resulting from the Covid-19 pandemic 
will affect the epidemiology of seasonal RVI in SOT recipients will need to be closely monitored 
in the upcoming years.3   
We found RVI to be associated with significant morbidity, resulting in 17.9 hospital admissions 
per 1000 person-years. Influenza was overall the most relevant infection, accounting for 33% of 
all hospital admissions, 44% of all ICU admissions, and 33% of all 30-day all-cause deaths. In 
high income countries, influenza is estimated to be responsible for up to 76.4 hospitalizations due 
to LRTI and two up to eight respiratory deaths per 100 000 habitants annually in the general 
population.4,26 While keeping in mind some potential confounders, such as more frequent hospital 
admission and higher rate of comorbidities in SOT recipients, we observed 8- and 23-fold higher 
hospital admission and at least 2- and 6-fold higher mortality rates with influenza and RVI, 
respectively. These data confirm the severe burden of disease associated with RVI, and with 
influenza in particular, in SOT recipients. Better influenza vaccine coverage, development of 
improved vaccination strategies, administration postexposure antiviral prophylaxis, and use of 
personal protective equipment (such as mask wearing) in high-risk situations may reduce the 
burden of disease associated with RVI in SOT recipients. Whether these preventive measures are 
effective in improving patient and graft survival will need to be assessed in specifically designed 
prospective studies.
In the analysis of severe cases of RVI, nosocomial acquisition was an independent risk factor for 
ICU admission. Although RVI are typically community-acquired, 7% were nosocomial in our 
cohort, underscoring the importance of adequate infection control measures. Although the cut-off 
defining nosocomial RVI is widely used in infection control (2 to 3 days), incubation period vary 
across different respiratory virus, potentially resulting in misclassification of some episodes. 
However, since median time from hospital admission to RVI was 12.5 days, this probably did not 
significantly affect our results. Bacterial co-infection and radiologic infiltrates were additional 
important risk factors for ICU admission. Since we were not able to differentiate among 
radiographic patterns, and given the low yield of microbiological tests for the diagnosis of 
bacterial pneumonia, it cannot be excluded that most of the ICU admissions were ultimately 
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Importantly, we found that RVI in SOT recipients were associated with a two-fold increased risk 
of graft failure or death. Viral infections may induce direct parenchymal tissue damage but also 
modulate cytokine production and thereby promote inflammatory or fibrotic changes in the 
allograft, both of the mechanisms potentially leading to graft dysfunction and ultimately to graft 
loss.7 Acute cellular rejection may be triggered by the generation of alloreactive T-cells resulting 
from viral infection or the reduction in immunosuppression to achieve viral clearance.27 In our 
study acute rejection was associated with graft failure or death, but whether the effect of RVI is 
mediated by an increased risk of rejection remains unknown. An association between RVI and 
acute rejection might support this hypothesis and deserve to be further investigated. Additional 
mechanisms indirectly triggered by RVI, including ischemia due to hemodynamic or respiratory 
instability, toxicity of drugs used for the treatment of infections, and complications related to 
hospital admission (i.e. catheter-associated or C. difficile infections, or simply deconditioning), 
maybe also explain the impact of RVI on graft and patients survival, particularly in non-lung 
transplant recipients.7,17 
In lung transplant recipients, a link between RVI and acute cellular rejection has not been 
consistently demonstrated by clinical studies.10,12,22 However, a two to three-fold increased risk for 
CLAD has been recently shown in adult lung transplant recipients with RVI.9,11,28,29 In our study, 
only LRTI were associated with an increased risk of graft failure or death in lung transplant 
recipients, in agreement with previous findings for CLAD.9,11,29 The significant proportion of 
asymptomatic and mild RVI in lung transplant recipients probably explains the absence of effect 
when all RVI were considered in this population, arguing against a systematic screening of 
asymptomatic lung transplant recipients. To date, there are no studies that have systematically 
assessed the impact of RVI on patient and graft survival in non-lung transplant recipients. We 
found an increased risk of graft failure or death in patients with influenza, which is in concordance 
with the reduced graft failure free survival observed in kidney transplant recipients unvaccinated 
against influenza.30 
Beside influenza, we observed an increased morbidity in terms of progression to LRTI, hospital 
admission and presence of radiologic infiltrates with RSV, HPIV, and HMPV, and a higher 
proportion of asymptomatic carriers with picornavirus or seasonal HCoV, in agreement with 
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severe RVI, testing for picornavirus and seasonal HCoV may not be necessary, also considering 
the absence of specific therapeutic options.   
We acknowledge some limitations of our study. First, testing for RVI was based on the clinical 
judgement of the physician and not performed following a specific prospective protocol. 
Heterogeneity in testing indication and choice of assay (i.e. use of influenza specific test versus 
use of multiplex panels) potentially led to an underrepresentation of milder infections as well as 
viral infections other than influenza or RSV, particularly in non-lung transplant recipients or for 
RVI managed exclusively in the outpatient setting. Second, variables not prospectively collected 
within our cohort were retrospectively retrieved through chart review, leading to some missing 
data (in particular regarding the clinical characteristics of RVI) and not allowing the inclusion of 
some important covariates, such as influenza vaccination status. Third, our approach might 
overestimate the effect of RVI, in particular in presence of bacterial or fungal co-infection which 
may ultimately be responsible for the impaired outcomes seen in some of these episodes. Finally, 
despite the large number of potential confounders included in our model, we cannot exclude that a 
diagnosis bias of RVI in sicker patients (i.e. patients with allograft dysfunction) contributed to our 
observations. Nevertheless, the strength of this study is the high number of SOT recipients 
included from different centers and type of transplant, and of RVI collected over several seasons. 
Because 93% of Swiss SOT recipients since 2008 are enrolled in this nationwide cohort with 
probably the vast majority of the clinically significant infections detected, the results are 
representative of the burden of disease of RVI in SOT recipients in real life in our country.
In summary, respiratory viral infections generate significant morbidity in SOT recipients and 
potentially contribute in impairing the outcomes of transplantation. Our results suggest that the 
implementation of improved preventive strategies against RVI, and in particular influenza, is an 
important need in contemporary transplant medicine.
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FIGURE LEGENDS
Figure 1: Cumulative incidence of respiratory viral infections according to type of 
transplantation and most frequent respiratory virus. 
Cumulative incidence and 95% confidence interval of first occurrence of respiratory viral infection 
in lung (red line and light red shading) and non-lung (blue-line and light blue shading) transplant 
recipients treating death and graft failure as competing risks (A). Cumulative incidence of first 
occurrence of influenza, picornavirus, human coronavirus, RSV, HPIV, and HMPV in lung (B) 
and non-lung (C) transplant recipients treating death and graft failure as competing risks. HCoV, 
human coronavirus; HMPV, human metapneumovirus; HPIV, human parainfluenza virus; RSV, 
respiratory syncytial virus.
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Bar plot show respiratory viruses detected according to the month of the year. All the detected 
respiratory virus are shown in case of simultaneous infection with more than one respiratory virus. 
HAdV, human adenovirus; HBoV, human bocavirus; HCoV, human coronavirus; HMPV, human 
metapneumovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus.
Figure 3: Cox proportional-hazards models for graft-failure or death. Forest plots illustrate 
the log-transformed adjusted-hazard ratios and 95% confidence intervals for the Cox proportional-
hazards models for graft failure or death. Adjusted-hazard ratios and 95% confidence intervals are 
indicated on the right columns. The model was fit on all SOT recipients in our study population 
(A), in lung transplant recipients only (B), and in non-lung transplant recipients only (C). Bacterial 
infection refers to bacterial infection in the transplant or bacteremia, and viral infection refers to 
allograft specific viral infection (BK virus in kidney transplant and B and C viral hepatitis in liver 
transplant, respectively). Age refers to increasing age by 10 years. F, female; CMV, 
cytomegalovirus; RVI, respiratory viral infection; LRTI, lower respiratory tract infection; aHR, 
adjusted-hazard-ratio; CI, confidence interval.
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TABLES













Sex (Male), n (%) 2107 (64.0%) 1856 (64.5%) 251 (60.3%)
Type of transplantation, n (%)    
    Kidney 1826 (55.4%) 1663 (57.8%) 163 (39.2%)
    Liver 685 (20.8%) 629 (21.9%) 56 (13.5%)
    Heart 249 (7.6%) 214 (7.4%) 35 (8.4%)
    Lunga 334 (10.1%) 183 (6.4%) 151 (36.3%)
    Combinedb 161 (4.9%) 153 (5.3%) 8 (1.9%)
    Otherc 39 (1.2%) 36 (1.3%) 3 ( 0.7%)
Living donor, n (%) 806 (24.5%) 744 (25.9%) 62 (14.9%)
Re or Second transplantation at enrollment, n 
(%)
389 (11.8%) 335 (11.6%) 54 (13.0%)
    Re transplantation 316 (9.6%) 277 (9.6%) 39 (9.4%)
    Second transplantation 73 (2.2%) 58 (2.0%) 15 (3.6%)
Induction immunosuppression, n (%)    
    Basiliximab 2288 (69.5%) 1965 (68.3%) 323 (77.6%)
    Anti-lymphocyte globulin 798 (24.2%) 714 (24.8%) 84 (20.2%)
Maintenance immunosuppressiond, n (%)    
    Tacrolimus 2360 (71.7%) 2104 (73.2%) 256 (61.5%)
    Cyclosporin 799 (24.3%) 646 (22.5%) 153 (36.8%)
    Mycophenolate 2961 (89.9%) 2585 (89.9%) 376 (90.4%)
    Azathioprine 54 (1.6%) 45 (1.6%) 9 (2.2%)
    mTOR inhibitors 124 (3.8%) 112 (3.9%) 12 (2.9%)
    Prednisone 3006 (91.3%) 2612 (90.8%) 394 (94.7%)
CMV serostatus at enrollmente, n (%)    
    D+/R- 655 (20.0%) 568 (19.8%) 87 (20.9%)
    R+ 1968 (60.0%) 1713 (59.8%) 255 (61.3%)
    D-/R- 657 (20.0%) 583 (20.4%) 74 (17.8%)
Follow-up in years, median (IQR) 3.40 (1.61-5.56) 3.31 (1.45-5.50) 4.30 (2.53-5.87)
Patients with graft loss, n (%) 325 (9.9%) 273 (9.5%) 52 (12.5%)









This article is protected by copyright. All rights reserved
Death with functioning allograft, n (%) 287 (8·7%) 243 (8.4%) 44 (10.6%)
SOT, solid organ transplant; RVI, respiratory viral infection; IQR, interquartile range; mTOR mammalian target of 
rapamycin; CMV, cytomegalovirus; D, donor; R, recipient.
a Including 6 combined lung transplant recipients (Lung-Liver [3], Lung-Heart [1], Lung-Kidney [1], and Lung-Liver-
Islets [1]
b Including Kidney-Pancreas (78), Kidney-Kidney (33), Kidney-Liver (30), Kidney-Islets (11), Kidney-Heart (4), 
Pancreas-Small  Bowel (2), Kidney-Kidney-Pancreas (2), Kidney-Islets-Liver (1)
c Islets (28), Pancreas (10), and Small Bowel (1).
d Maintenance immunosuppression represent immunosuppression at hospital discharge after transplantation
e Baseline CMV serostatus was unknown for 14 patients
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Table 2: Characteristics and short-term outcomes of respiratory viral infections.
Virus
 




















Nosocomial infection, n (%) 50 (7.2%) 16 (8.6%) 9 (11.7%) 2 (4.1%) 1 (3.2%) 9 (3.8%) 5 (7.6%) 0.122
Asymptomatic, n (%) 56 (8.0%) 4 (2.2%) 4 (5.2%) 2 (4.1%) 1 (3.2%) 28 (11.9%) 13 (19.7%) <0.001
URTI, n (%) 250 (35.9%) 85 (45.7%) 21 (27.3%) 16 (32.7%) 6 (19.4%) 84 (35.6%) 22 (33.3%) 0.014
LRTI, n (%) 242 (34.8%) 68 (36.6%) 32 (41.6%) 24 (49.0%) 20 (64.5%) 56 (23.7%) 17 (25.8%) <0.001
Unknown, n (%) 148 (21.3%) 29 (15.6%) 20 (26.0%) 7 (14.3%) 4 (12.9%) 68 (28.8%) 14 (21.2%) 0.011
Radiology, n (%) 313 (45.0%) 112 (60.2%) 40 (51.9%) 25 (51.0%) 13 (41.9%) 82 (34.7%) 20 (30.3%) <0.001
Radiologic infiltrate, n (%) 132 (19.0%) 37 (19.9%) 13 (16.9%) 14 (28.6%) 8 (25.8%) 33 (14.0%) 11 (16.7%) 0.147
Bronchoscopy, n (%) 103 (14.8%) 14 (7.5%) 15 (19.5%) 9 (18.4%) 8 (25.8%) 41 (17.4%) 10 (15.2%) 0.018
Bacterial co-infection, n (%) 53 (7.6%) 13 (7.0%) 4 (5.2%) 5 (10.2%) 2 (6.5%) 20 (8.5%) 2 (3.0%) 0.626
Fungal co-infection, n (%) 24 (3.4%) 4 (2.2%) 5 (6.5%) 3 (6.1%) 2 (6.5%) 5 (2.1%) 2 (3.0%) 0.257
Hospital admissiona, n (%) 221 (34.2%) 73 (42.9%) 29 (42.6%) 20 (42.6%) 14 (46.7%) 53 (23.3%) 14 (23.0%) 0.001
ICU admissiona, n (%) 27 (3.9%) 12 (6.5%) 3 (3.9%) 1 (2.0%) 1 (3.3%) 6 (2.6%) 1 (1.5%) 0.295
Mechanical ventilation, n 
(%)
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30-days graft failureb, n (%) 4 (0.6%) 1 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (1.5%) 0.841
30-days deathb, n (%) 6 (0.9%) 2 (1.1%) 0 (0.0%) 0 (0.0%) 1 (3.2%) 2 (0.8%) 1 (1.5%) 0.660
RVI respiratory viral infection; HCoV, human coronavirus; HMPV, human metapneumovirus; HPIV, human parainfluenza virus; Picorna, Picornavirus; RSV, respiratory syncytial 
virus; IQR, interquartile range; URTI, upper respiratory tract infection; LRTI, lower respiratory tract infectious infection; ICU, intensive care unit.
a Nosocomial infections (n=50) and infections occurring during ICU stay (n=5) were excluded from the calculation of hospital and ICU admission rates. 
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0.0072 1.3 (1.0-1.8) 0.057











  <0.00001   
     Kidney 186 (28.0%) 9 (33.3%)   
     Liver  80 (12.0%)  2 (7.4%)   
     Heart  40 (6.0%)  1 (3.7%)   
     Lung  340 (51.2%)  10 (37.0%)  1.3 (0.48-3.3) 0.64 
     Combined  17 (2.6%)  3 (11.1%)   
     Other  1 (0.2%)  2 (7.4%)   
Influenza, n (%)  173 (26.1%)  12 (44.4%) 0.045 2.4 (0.92-6.0) 0.072 
RSV, n (%)  74 (11.1%)  4 (14.8%) 0.53   
HPIV, n (%)  59 (8.9%)  1 (3.7%) 0.50   
HMPV, n (%)  32 (4.8%)  2 (7.4%) 0.39   
Picornavirus, n (%)  263 (39.6%)  8 (29.6%) 0.32   
HCoV, n (%)  85 (12.8%)  1 (3.7%) 0.23   
Nosocomial 
infection, n (%)
37 (5.6%) 8 (29.6%) 0.00015 4.8 (1.7-13.0) 0.0028
Radiologic infiltrate, 
n (%)
108 (16.3%) 19 (70.4%) <0.00001 5.4 (2.1-15.0) 0.0007
Bacterial co-
infection, n (%)
42 (6.3%) 11 (40.7%) <0.00001 5.1 (1.8-14.0) 0.0016
Fungal co-infection, 
n (%)




9 (1.4%) 1 (3.7%) 0.33   
Maintenance 
immunosuppressiona, 
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n (%)
     Tacrolimus 388 (58.4%) 13 (48.1%) 0.32   
     Cyclosporin 247 (37.2%) 11 (40.7%) 0.69   
     Mycophenolate 562 (84.6%) 23 (85.2%) 1.00   
     Prednisone 556 (83.7) 23 (85.2) 1.00   
     mTOR inhibitor 31 (4.7%) 0 (0.0%) 0.63   
Previous rejectionb, n 
(%)
84 (12.7%) 2 (7.4%) 0.56   
In univariate analysis categorical and continuous variables were compared using respectively Fischer’s exact test, and 
t test or Mann-Whitney U test, as appropriate. Multivariable logistic regression was used for multivariable analysis. 
ICU, intensive care unit; OR, odds ratio; CI, confidence interval; IQR, interquartile range; M, male; HCoV, human 
coronavirus; HMPV, human metapneumovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus; ; 
mTOR, mammalian target of rapamycin
a Maintenance immunosuppression at time of infection
b Acute rejection within 30 days before respiratory viral infection
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